Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues

This article was originally published in The Tan Sheet

Executive Summary

FDA's drug center referred its review of Johnson & Johnson's manufacturing operations to the Office of Criminal Investigations, which will determine whether there is criminal liability in the quality control lapses that led to extensive recalls of OTC drugs

Related Content

J&J Separates U.S. OTCs In "Unorthodox" Reorg To Get McNeil Back On Track
Schumer Bill Would Prohibit Sale Of Recalled Products
J&J Recalled To Capitol Hill As Besieged Consumer Group Chair Retires
Congress Hopes To Land J&J Chief Weldon For Second Recall Inquiry
J&J Expands Contaminated Packaging Recalls, Stoking House Investigation
Congress Wants More Answers From J&J On "Phantom Recall"
FDA Targeting Execs With Criminal Charges For Adulterated/Misbranded Goods
Towns wants answers on J&J's alleged "phantom recall"
FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls
FDA Agrees With GAO Recommendations To Give Prosecutions Higher Priority





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts